Citius Pharmaceuticals (CTXR) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Niki BioSolutions (NIKI) over the past year, losing 62.0% versus a loss of 82.1%. Over five years, NIKI leads with a -98.3% price change compared with -99.1% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($13.7 million vs $12.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | NIKI |
|---|---|---|
| Share price | $0.4994 | $4.00 |
| Market cap | $13.71M | $12.47M |
| 1-day change | +2.19% | -7.41% |
| YTD return | -37.10% | -59.25% |
| 1-year return | -61.97% | -82.07% |
| 5-year return | -99.06% | -98.33% |
| EPS (TTM) | $-1.75 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $24.00 |
| 52-week low | $0.469 | $4.00 |
| Distance from 52-week high | -77.20% | -83.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +700.96% | — |
| Average volume | 527.79K | 157.52K |
| Shares outstanding | 27.45M | 2.94M |
| Employees | 23 | 1 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed NIKI by 20.1 percentage points over the past year.
- The two companies sit in different sectors: Citius Pharmaceuticals in Health Care and Niki BioSolutions in Industrials.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
CTXR vs NIKI FAQ
Which is bigger, Citius Pharmaceuticals or Niki BioSolutions?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.71M compared with $12.47M for Niki BioSolutions (NIKI).
Which stock has performed better over the past year, CTXR or NIKI?
CTXR returned -61.97% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Niki BioSolutions in the same industry?
No. Citius Pharmaceuticals is in the Health Care sector, while Niki BioSolutions is in Industrials.